Systematic review of percutaneous closure versus medical therapy in patients with cryptogenic stroke and patent foramen ovale

BMJ Open

Volumn 4, Issue 3, 2014, Pages

  Spencer, Frederick A ^a   Lopes, Luciane C ^b   Kennedy, Sean A ^a   Guyatt, Gordon ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF SOROCABA   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; THIENOPYRIDINE DERIVATIVE; TICLOPIDINE; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT;

ARTICLE; ATRIAL SEPTAL OCCLUDER; BLEEDING; CEREBROVASCULAR ACCIDENT; ECHOCARDIOGRAPHY; HEART ATRIUM SEPTUM DEFECT; HUMAN; INTERNATIONAL NORMALIZED RATIO; OUTCOME ASSESSMENT; PATENT FORAMEN OVALE; SECONDARY PREVENTION; SEPTAL OCCLUDER; SYSTEMATIC REVIEW; TRANSIENT ISCHEMIC ATTACK; VENOUS THROMBOEMBOLISM; COMPARATIVE STUDY; FORAMEN OVALE, PATENT; HEART SURGERY; ISCHEMIC ATTACK, TRANSIENT; PROCEDURES; RECURRENT DISEASE; STROKE;

ANTICOAGULANTS; CARDIAC SURGICAL PROCEDURES; FORAMEN OVALE, PATENT; HUMANS; ISCHEMIC ATTACK, TRANSIENT; PLATELET AGGREGATION INHIBITORS; RECURRENCE; SECONDARY PREVENTION; STROKE;

EID: 84897529753     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2013-004282     Document Type: Article

References (25)

1. Webster MW, Chancellor AM, Smith HJ, et al. Patent foramen ovale in young stroke patients. Lancet 1988;2:11-12.
2. Lechat P, Mas JL, Lascault G, et al. Prevalence of patent foramen ovale in patients with stroke. N Engl J Med 1988;318:1148-52.
3. Khairy P, O'Donnell CP, Landzberg MJ. Transcatheter closure versus medical therapy of patent foramen ovale and presumed paradoxical thromboemboli: a systematic review. Ann Intern Med 2003;139:753-60. (Pubitemid 38129075)
4. Furlan AJ, Reisman M, Massaro J, et al. Closure or medical therapy for cryptogenic stroke with patent foramen ovale. N Engl J Med 2012;366:991-9.
5. Carroll JD, Saver JL, Thaler DE, et al. Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. N Engl J Med 2013;368:1092-100.
6. Meier B, Kalesan B, Mattle HP, et al. Percutaneous closure of patent foramen ovale in cryptogenic embolism. N Engl J Med 2013;368:1083-91.
7. Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928.
8. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336:924-6. (Pubitemid 351632017)
9. Guyatt GH, Oxman AD, Vist G, et al. GRADE guidelines: 4. Rating the quality of evidence - study limitations (risk of bias). J Clin Epidemiol 2011;64:407-15.
10. Guyatt GH, Oxman AD, Kunz R, et al. GRADE guidelines 6. Rating the quality of evidence - imprecision. J Clin Epidemiol 2011;64:1283-93.
11. Guyatt GH, Oxman AD, Kunz R, et al. GRADE guidelines: 7. Rating the quality of evidence - inconsistency. J Clin Epidemiol 2011;64:1294-302.
12. Guyatt GH, Oxman AD, Kunz R, et al. GRADE guidelines: 8. Rating the quality of evidence - indirectness. J Clin Epidemiol 2011;64:1303-10.
13. Guyatt GH, Oxman AD, Montori V, et al. GRADE guidelines: 5. Rating the quality of evidence - publication bias. J Clin Epidemiol 2011;64:1277-82.
14. Akl EA, Briel M, You JJ, et al. Potential impact on estimated treatment effects of information lost to follow-up in randomised controlled trials (LOST-IT): systematic review. BMJ 2012;344:e2809.
15. Murad MH, Montori VM, Walter SD, et al. Estimating risk difference from relative association measures in meta-analysis can infrequently pose interpretational challenges. J Clin Epidemiol 2009;62:865-7.
16. Geng EH, Emenyonu N, Bwana MB, et al. Sampling-based approach to determining outcomes of patients lost to follow-up in antiretroviral therapy scale-up programs in Africa. JAMA 2008;300:506-7.
17. Sun X, Briel M, Walter SD, et al. Is a subgroup effect believable? Updating criteria to evaluate the credibility of subgroup analyses. BMJ 2010;340:c117.
18. Pineda AM, Nascimento FO, Yang SC, et al. A meta-analysis of transcatheter closure of patent foramen ovale versus medical therapy for prevention of recurrent thromboembolic events in patients with cryptogenic cerebrovascular events. Catheter Cardiovasc Interv 2013;82:968-75.
19. Kitsios GD, Thaler DE, Kent DM. Potentially large yet uncertain benefits: a meta-analysis of patent foramen ovale closure trials. Stroke 2013;44:2640-3.
20. Khan AR, Bin Abdulhak AA, Sheikh MA, et al. Device closure of patent foramen ovale versus medical therapy in cryptogenic stroke: a systematic review and meta-analysis. JACC Cardiovas Interv 2013;6:1316-23.
21. Aryal MR, Pradhan R, Pandit AA, et al. A 'teapot' atrial septal aneurysm with spontaneous thrombus in an asymptomatic patient. Circulation 2013;128:e409-10.
22. Schneider B, Hanrath P, Vogel P, et al. Improved morphologic characterization of atrial septal aneurysm by transesophageal echocardiography: relation to cerebrovascular events. J AmColl Cardiol 1990;16:1000-9. (Pubitemid 20353426)
23. Cujec B, Mainra R, Johnson DH. Prevention of recurrent cerebral ischemic events in patients with patent foramen ovale and cryptogenic strokes or transient ischemic attacks. Can J Cardiol 1999;15:57-64. (Pubitemid 29080518)
24. Orgera MA, O'Malley PG, Taylor AJ. Secondary prevention of cerebral ischemia in patent foramen ovale: systematic review and meta-analysis. South Med J 2001;94:699-703. (Pubitemid 33645043)
25. Homma S, Sacco RL, Di Tullio MR, et al. Effect of medical treatment in stroke patients with patent foramen ovale: patent foramen ovale in Cryptogenic Stroke Study. Circulation 2002;105:2625-31. (Pubitemid 34596039)